Moderna eyes combined Covid-19, flu booster by 2023
Moderna CEO Stéphane Bancel also said an Omicron-specific Covid-19 vaccine will enter clinical development in a matter of weeks.
By
Special Focus
Latest in
Special Focus
Can DreamTec turn its bacteria-based oral Covid-19 vaccine into a reality?
DreamTec’s vaccine capsule contains bacterial spores studded with the SARS-CoV-2 receptor binding domain.
By
UK grants world-first approval to Covid-19 pill molnupiravir
Molnupiravir is the first oral antiviral medication to be approved for the treatment of Covid-19.
By
Molnupiravir: long-term safety questions linger as approvals approach
Some experts have concerns about the safety of Merck’s investigational Covid-19 antiviral molnupiravir.
By
Most of Latin America, Caribbean left behind in Merck’s oral Covid-19 antiviral deal
Many upper middle-income countries fall between the cracks after a recent landmark contract opened molnupiravir access to 105 countries.
By
Can Rigel’s bleeding disorder drug fostamatinib cross over into Covid-19?
Experts are optimistic of fostamatinib’s potential in hospitalised Covid-19 though they note available data is from a 59-patient trial.
By
In conversation: South Africa Covid-19 vaccine expert Shabir Madhi
Covid-19 vaccine investigator Shabir Madhi discusses South Africa’s susceptibility to a fourth wave, and much more.
By
CyanVac eyes fundraise for parainfluenza-vectored Covid-19 vaccine after December data
CyanVac’s CVXGA1 is a nasally administered Covid-19 vaccine that uses a parainfluenza virus 5 vector.
By